115,817 Shares in Blueprint Medicines Co. (NASDAQ:BPMC) Bought by Wealthfront Advisers LLC

Wealthfront Advisers LLC bought a new position in shares of Blueprint Medicines Co. (NASDAQ:BPMC) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 115,817 shares of the biotechnology company’s stock, valued at approximately $10,102,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Torray Investment Partners LLC grew its stake in Blueprint Medicines by 1.1% during the 4th quarter. Torray Investment Partners LLC now owns 16,499 shares of the biotechnology company’s stock worth $1,439,000 after buying an additional 186 shares during the last quarter. Franklin Resources Inc. lifted its position in Blueprint Medicines by 0.7% during the 3rd quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company’s stock worth $3,259,000 after acquiring an additional 265 shares during the period. Quarry LP acquired a new stake in Blueprint Medicines during the 3rd quarter worth about $32,000. Van ECK Associates Corp lifted its position in Blueprint Medicines by 48.2% during the 4th quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock worth $97,000 after acquiring an additional 363 shares during the period. Finally, PNC Financial Services Group Inc. lifted its position in Blueprint Medicines by 31.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,650 shares of the biotechnology company’s stock worth $144,000 after acquiring an additional 399 shares during the period.

Analyst Upgrades and Downgrades

A number of brokerages have commented on BPMC. JPMorgan Chase & Co. lifted their price target on Blueprint Medicines from $126.00 to $129.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. StockNews.com cut Blueprint Medicines from a “hold” rating to a “sell” rating in a report on Monday, March 3rd. HC Wainwright reissued a “buy” rating and issued a $135.00 price objective on shares of Blueprint Medicines in a report on Friday, February 14th. Stephens reissued an “overweight” rating and issued a $140.00 price objective on shares of Blueprint Medicines in a report on Thursday, January 2nd. Finally, JMP Securities reissued a “market outperform” rating and issued a $125.00 price objective on shares of Blueprint Medicines in a report on Friday, February 14th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $125.21.

Blueprint Medicines Trading Up 1.2 %

Blueprint Medicines stock opened at $87.76 on Wednesday. The company has a 50 day moving average price of $99.39 and a 200 day moving average price of $94.12. Blueprint Medicines Co. has a 52 week low of $80.68 and a 52 week high of $121.90. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85. The firm has a market capitalization of $5.61 billion, a price-to-earnings ratio of -81.26 and a beta of 0.58.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. Research analysts forecast that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Insider Buying and Selling at Blueprint Medicines

In other news, insider Ariel Hurley sold 1,819 shares of the firm’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $93.26, for a total transaction of $169,639.94. Following the transaction, the insider now owns 14,967 shares in the company, valued at approximately $1,395,822.42. This trade represents a 10.84 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kate Haviland sold 1,446 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total transaction of $159,407.04. Following the transaction, the chief executive officer now owns 149,378 shares in the company, valued at $16,467,430.72. This represents a 0.96 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 48,427 shares of company stock valued at $4,837,801 in the last quarter. Company insiders own 4.21% of the company’s stock.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.